GNLX — Genelux Corporation Common Stock

Genelux Corporation Common Stock (GNLX) is a biotechnology company listed on NASDAQ. It is led by Thomas Zindrick J.D., based in 2625 Townsgate Road, Westlake Village, CA, United States, 91361, with about 24 employees. Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Net income was -$8.0M. GNLX currently screens at market cap $130.6M.

Use this GNLX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GNLX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GNLX SEC filings page. Lician reads the product cache first so this HTML stays unique to Genelux Corporation Common Stock even when a live quote feed is slow.